.Attribute Medication, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint asks for addition of people with MASLD and measurement of liver end results in cardio-- kidney-- metabolic trials, when information advise mechanistically conceivable perks and professional safety and security-- and also details factors for trial style and also governing approval.